Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.
复制标题
DOI:
10.1016/j.jvacx.2022.100165
复制
发表时间:
2022-08
期刊:
影响因子:
3.8
通讯作者:
Vallejo, Alejandro
中科院分区:
文献类型:
--
作者:
Casado, Jose L.;Vizcarra, Pilar;Haemmerle, Johannes;Velasco, Hector;Martin-Hondarza, Adrian;Rodriguez-Dominguez, Mario J.;Velasco, Tamara;Martin, Sara;Romero-Hernandez, Beatriz;Fernandez-Escribano, Marina;Vallejo, Alejandro
Lack of CD4 T-cell response to first/second dose of mRNA vaccine was observed in 21% and 12% of health care workers (HCWs). T-cell response was greater in frequency/magnitude in HCWs with pre-existing immunity, due due to infection or cross-reactivity. Pre-existing immunity correlated with the magnitude of specific antibodies production after vaccination. Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4+ and CD8+ T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4+ T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.
登录
查看更多内容
影响因子:
32.4
作者:
Sette, Alessandro;Moutaftsi, Magdalini;Crotty, Shane
通讯作者:
Crotty, Shane
影响因子:
30.3
作者:
Tauzin A;Nayrac M;Benlarbi M;Gong SY;Gasser R;Beaudoin-Bussières G;Brassard N;Laumaea A;Vézina D;Prévost J;Anand SP;Bourassa C;Gendron-Lepage G;Medjahed H;Goyette G;Niessl J;Tastet O;Gokool L;Morrisseau C;Arlotto P;Stamatatos L;McGuire AT;Larochelle C;Uchil P;Lu M;Mothes W;De Serres G;Moreira S;Roger M;Richard J;Martel-Laferrière V;Duerr R;Tremblay C;Kaufmann DE;Finzi A
通讯作者:
Finzi A
影响因子:
32.4
作者:
Painter MM;Mathew D;Goel RR;Apostolidis SA;Pattekar A;Kuthuru O;Baxter AE;Herati RS;Oldridge DA;Gouma S;Hicks P;Dysinger S;Lundgreen KA;Kuri-Cervantes L;Adamski S;Hicks A;Korte S;Giles JR;Weirick ME;McAllister CM;Dougherty J;Long S;D'Andrea K;Hamilton JT;Betts MR;Bates P;Hensley SE;Grifoni A;Weiskopf D;Sette A;Greenplate AR;Wherry EJ
通讯作者:
Wherry EJ
影响因子:
24.8
作者:
Reynolds CJ;Swadling L;Gibbons JM;Pade C;Jensen MP;Diniz MO;Schmidt NM;Butler DK;Amin OE;Bailey SNL;Murray SM;Pieper FP;Taylor S;Jones J;Jones M;Lee WJ;Rosenheim J;Chandran A;Joy G;Di Genova C;Temperton N;Lambourne J;Cutino-Moguel T;Andiapen M;Fontana M;Smit A;Semper A;O'Brien B;Chain B;Brooks T;Manisty C;Treibel T;Moon JC;COVIDsortium investigators;Noursadeghi M;COVIDsortium immune correlates network;Altmann DM;Maini MK;McKnight Á;Boyton RJ
通讯作者:
Boyton RJ
影响因子:
2.6
作者:
Aksoy, Sercan;Harputluoglu, Hakan;Barista, Ibrahim
通讯作者:
Barista, Ibrahim